ReviewFrontiers in microbiology2019
Subversion of the Immune Response by Human Pathogenic Mycoplasmas.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Mycoplasma pneumoniae infections in the Post-COVID era: recent advances from pathogenesis to clinical management.Infection · 2026Review
- Application of Clinical Indicators in the Early Prediction of RefractoryClinical pediatrics · 2026Article
- MUREAPLEXE: A multiplex recombinant antigen-based ELISA expanding the serological detection spectrum of urogenital mycoplasmas.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Nuclear IL-33 amplifies NF-κB signaling to drive neutrophil recruitment and activation in the endocervical epithelium duringFrontiers in immunology · 2026Article
- When less is more: cell size reduction as a metabolic lifeline inFrontiers in microbiology · 2026Article
- Drug resistance ofFrontiers in cellular and infection microbiology · 2026Review
- Proinflammatory Cytokines in Women with PCOS in Atypical Pathogen Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases.Journal of translational autoimmunity · 2025Review
- Changes of serum inflammatory markers and immune function in children with bronchial asthma complicated with mycoplasma pneumoniae infection before and after treatment and their clinical significance.Pakistan journal of medical sciences · 2025Article
- Clinical Efficacy of Qingke Mixture in Treating Mycoplasma Pneumonia in Children: A Randomized Controlled Trial.International journal of general medicine · 2025Article
- Article
- Article
- Cryo-electron tomography reveals the binding and release states of the major adhesion complex from Mycoplasma genitalium.PLoS pathogens · 2023Article
- Mechanisms of Long-Term Persistence of Mycoplasmas in Children with Asthma.Microorganisms · 2023Article
- Unveiling the stealthy tactics: mycoplasma's immune evasion strategies.Frontiers in cellular and infection microbiology · 2023Review
- Clinical analysis of hospital acquired mycoplasma pneumoniae infection after cardiac surgery: a case series.Journal of thoracic disease · 2022Article
- DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection.Applied microbiology and biotechnology · 2022Article
- Vaccinomics-Aided Development of a Next-Generation Chimeric Vaccine against an Emerging Threat:Vaccines · 2022Article
- Genome-Wide Association Study of Nucleotide Variants Associated with Resistance to Nine Antimicrobials inMicroorganisms · 2022Article
- Bacteria-Mediated Oncogenesis and the Underlying Molecular Intricacies: What We Know So Far.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasmas are a large group of prokaryotes which is believed to be originated from Gram-positive bacteria via degenerative evolution, and mainly capable of causing a wide range of human and animal infections. Although innate immunity and adaptive immunity play crucial roles in preventing mycoplasma infection, immune response that develops after infection fails to completely eliminate this bacterium under certain circumstances. Thus, it is reasonable to speculate that mycoplasmas employ some mechanisms to deal with coercion of host defense system. In this review, we will highlight and provide a comprehensive overview of immune evasion strategies that have emerged in mycoplasma infection, which can be divided into four aspects: (i) Molecular mimicry and antigenic variation on the surface of the bacteria to evade the immune surveillance; (ii) Overcoming the immune effector molecules assaults: Induction of detoxified enzymes to degradation of reactive oxygen species; Expression of nucleases to degrade the neutrophil extracellular traps to avoid killing by Neutrophil; Capture and cleavage of immunoglobulins to evade humoral immune response; (iii) Persistent survival: Invading into the host cell to escape the immune damage; Formation of a biofilm to establish a persistent infection; (iv) Modulation of the immune system to down-regulate the intensity of immune response. All of these features increase the probability of mycoplasma survival in the host and lead to a persistent, chronic infections. A profound understanding on the mycoplasma to subvert the immune system will help us to better understand why mycoplasma is so difficult to eradicate and ultimately provide new insights on the development of therapeutic regimens against this bacterium in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.